Toggle light / dark theme

Adeno-associated virus (AAV) is a well-known gene delivery tool with a wide range of applications, including as a vector for gene therapies. However, the molecular mechanism of its cell entry remains unknown. Here, we performed coarse-grained molecular dynamics simulations of the AAV serotype 2 (AAV2) capsid and the universal AAV receptor (AAVR) in a model plasma membrane environment. Our simulations show that binding of the AAV2 capsid to the membrane induces membrane curvature, along with the recruitment and clustering of GM3 lipids around the AAV2 capsid. We also found that the AAVR binds to the AAV2 capsid at the VR-I loops using its PKD2 and PKD3 domains, whose binding poses differs from previous structural studies. These first molecular-level insights into AAV2 membrane interactions suggest a complex process during the initial phase of AAV2 capsid internalization.

The small-scale FDA-cleared trial is designed to evaluate both the safety and initial efficacy of RB-ADSCs in nine patients with Alzheimer’s. Regeneration Biomedical’s CTAD presentation focused on the first three enrolled patients, who each received a single dose of RB-ADSCs delivered directly into the lateral ventricles of the brain using an “Ommaya reservoir” – a device implanted under the scalp to bypass the blood-brain barrier, a major obstacle in Alzheimer’s treatments.

Biomarker analysis at the 12-week mark demonstrated reductions in both p-Tau and amyloid-beta – two proteins strongly associated with Alzheimer’s disease progression. In cerebrospinal fluid (CSF) samples from the three patients, p-Tau levels decreased to “normal” levels, while amyloid PET scans also showed a reduction in amyloid buildup.

Regeneration Biomedical also reported its treatment produced signs of cognitive improvement, with two of the three patients showing increased Mini-Mental State Examination (MMSE) scores, a common measure of cognitive function.

In a groundbreaking Nature paper, researchers have developed synthetic regulatory sequences that could prevent targeted gene therapies from having effects in unwanted cell types.

More than methylation

While methylation is the most well-known regulator of gene expression, it isn’t the only thing that determines what is to be expressed when. Cis-regulatory elements (CREs), so called because they sit near the DNA sequences they regulate, are responsible for expressing the genes that are specific to each cell type [1]. While they are technically non-coding, as they do not directly code for functional proteins, CREs are critical to epigenomic function.

Murata is branching out from its usual ceramic components with the launch of flexible, stretchable electronics — a Stretchable Printed Circuit (SPC) platform it says is ideally positioned for wearable and medical devices.

In recent years, in the medical field, to make more accurate diagnoses, the…


Bendy, soft, stretchy devices target the wearable and medical markets.